ABSTRACT
PURPOSE: Chronic obstructive pulmonary disease (COPD) is a leading cause of death, and cardiovascular (CV) comorbidities play a role. Evidence of the pulmonary rehabilitation (PR) effect in reducing the CV risk (CVR) in COPD patients is limited. In this study, we aimed to determine the impact of an 8-week PR program (PRP) on the CVR of the overall population and to compare the impact on the exacerbator versus non-exacerbator patients. PATIENTS AND METHODS: This was a prospective study that included adults who had post-bronchodilator forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) (FEV1/FVC) ratio <70% and FEV1 <80% predicted, had quit smoking for at least 1 year and had a history of tobacco consumption greater than 10 packs/year, and were clinically stable in the last 8 weeks. Pre- and post-PRP assessments included respiratory function evaluation, laboratory tests, and exercise capacity assessment (6-minute walking test [6MWT]). CVR was assessed using different risk prediction models. RESULTS: A total of 50 patients (28 exacerbators and 22 non-exacerbators) completed the PRP (median age: 64.5 years, men: 72%; arterial hypertension: 70%, dyslipidemia: 30%, diabetes: 20%; CV disease (CVD): 24%. After the PRP, exacerbator patients showed a significant decrease in the CVR calculated by the COPDCoRi model (p<0.001); patients with ≥30-meter increase on the 6MWT showed statistically significant lower levels of glucose (p=0.004), HbA1c (p=0.004) and BODE index score (p=0.026) compared to patients with <30-meter increase. CONCLUSIONS: PR reduced certain modifiable CVR factors and CVD risk, especially in exacerbator patients.
ABSTRACT
Objetivo: Evaluar la efectividad de un programa de rehabilitación respiratoria (RR) multidisciplinar en pacientes con enfermedad pulmonar obstructiva crónica grave o muy grave preprograma RR, al terminar el programa y al año de haber realizado la RR midiendo los cambios producidos en: la capacidad de ejercicio (test de marcha), mejoría en la tolerancia al esfuerzo (volumen espiratorio forzado [FEV1]) y en la calidad de vida relacionada con la salud. Método: Diseño cuasi experimental con un solo grupo. Se incluyeron a pacientes con diagnóstico de enfermedad pulmonar obstructiva crónica grave o muy grave (estadios III y IV de la clasificación GOLD) que entraron en el programa de RR entre 2011 y 2012. Se recogieron datos demográficos, calidad de vida relacionada con la salud general (SF-36) y específica para enfermos respiratorios (Cuestionario Respiratorio St. George), FEV1% y test de capacidad de ejercicio (prueba de la marcha de 6min). La recogida de datos se realizó preprograma RR, al terminar el programa de RR y al año de haber acabado el programa. Resultados: No se observaron diferencias significativas en los valores de FEV1%. Respecto a la capacidad de ejercicio se observó un aumento de la distancia recorrida en el test de marcha, que se modificó significativamente después del entrenamiento, de 377±59,7 a 415±79m al año (p<0,01). Se observó una mejoría estadísticamente significativa en las 3 dimensiones del Cuestionario Respiratorio St. George. Las medias de las puntuaciones obtenidas de la calidad de vida relacionada con la salud mejoraron significativamente en todas las dimensiones excepto en la dimensión rol emocional del cuestionario SF-36. Conclusión Un programa de RR de 8 semanas de duración mejora la capacidad de realizar ejercicio, la disnea y la calidad de vida en pacientes con enfermedad pulmonar obstructiva crónica grave y muy grave (AU)
Objective: To evaluate the effectiveness of the multidisciplinary respiratory rehabilitation (RR) programme in patients with severe or very severe chronic obstructive pulmonary disease pre the RR programme, at the end of the programme and one year after the RR, measuring changes in ability to exercise (walking test), effort tolerance(forced expiratory volume (FEV1)) and health-related quality of life. Method: Quasi-experimental single group design. We included patients diagnosed with severe or very severe chronic obstructive pulmonary disease (stages III and IV of the GOLD classification) who entered the rehabilitation programme for the years 2011 and 2012. Demographic data, questionnaires on general health-related quality of life (SF-36) and specific to respiratory patients (St George's Respiratory Questionnaire), FEV1% and exercise capacity test (running test 6minutes) were collected. Data were collected before the RR programme, at the end of the RR programme and a year after completing the program. Results: No significant differences in FEV1% values were observed. Regarding exercise capacity, an increase in distance walked in the walking test was noted, which changed significantly after training, 377±59.7 to 415±79 m after one year (P<.01). A statistically significant improvement in mean scores of HRQoL was observed, except for the emotional role dimension of the SF-36 questionnaire. Conclusion: A pulmonary rehabilitation programme for 8 weeks improved the exercise capacity, dyspnoea and quality of life of patients with severe and very severe chronic obstructive pulmonary disease (AU)
Subject(s)
Humans , Rehabilitation Nursing/organization & administration , Pulmonary Disease, Chronic Obstructive/nursing , Pulmonary Disease, Chronic Obstructive/rehabilitation , Quality of Life , Health Promotion/organization & administration , Patient Education as Topic/organization & administration , Evaluation of the Efficacy-Effectiveness of Interventions , Surveys and Questionnaires , Dyspnea/complications , Dyspnea/nursing , Plethysmography/nursing , 28599ABSTRACT
OBJECTIVE: To evaluate the effectiveness of the multidisciplinary respiratory rehabilitation (RR) programme in patients with severe or very severe chronic obstructive pulmonary disease pre the RR programme, at the end of the programme and one year after the RR, measuring changes in ability to exercise (walking test), effort tolerance(forced expiratory volume (FEV1)) and health-related quality of life. METHOD: Quasi-experimental single group design. We included patients diagnosed with severe or very severe chronic obstructive pulmonary disease (stages III and IV of the GOLD classification) who entered the rehabilitation programme for the years 2011 and 2012. Demographic data, questionnaires on general health-related quality of life (SF-36) and specific to respiratory patients (St George's Respiratory Questionnaire), FEV1% and exercise capacity test (running test 6minutes) were collected. Data were collected before the RR programme, at the end of the RR programme and a year after completing the program. RESULTS: No significant differences in FEV1% values were observed. Regarding exercise capacity, an increase in distance walked in the walking test was noted, which changed significantly after training, 377±59.7 to 415±79 m after one year (P<.01). A statistically significant improvement in mean scores of HRQoL was observed, except for the emotional role dimension of the SF-36 questionnaire. CONCLUSION: A pulmonary rehabilitation programme for 8 weeks improved the exercise capacity, dyspnoea and quality of life of patients with severe and very severe chronic obstructive pulmonary disease.
Subject(s)
Pulmonary Disease, Chronic Obstructive/rehabilitation , Aged , Female , Humans , Male , Patient Care Team , Pulmonary Disease, Chronic Obstructive/physiopathology , Respiratory Function Tests , Severity of Illness Index , Treatment OutcomeABSTRACT
A large number of COPD patients are smokers. The particular characteristics of this group as well as their need to quit usually require psychological counselling and pharmacological treatment to achieve abstinence and, often, intensively. Little information is available about this issue. The main objective of the study was to evaluate the effectiveness of varenicline after 24 weeks of treatment, with continuous abstinence between weeks 9 and 24. This study was a post-authorization, open label, observational study of prospective follow-up. Patients included were smokers with severe or very severe COPD criteria who were treated with varenicline for 24 weeks, i.e. with a 12-week extension over the usual treatment. The outcomes in the population of subjects completing 24 weeks of follow-up were at week 24: continuous abstinence 36.8%, 7 days point prevalence abstinence 65.7%, and continuous smoking 31.5%.The outcomes in the intention-to-treat population included at baseline were: continuous abstinence 17.7% of patients, 7 days point prevalence abstinence 31.6%, continuous smoking 15.1% and not valid/unknown 51.8%. The mean CAT score at week 24 was 15 and reduction from the baseline was 3.77 (paired T test, p<0.01). The most common adverse events reported were nausea, vivid dreams, stomach ache, insomnia, headache and vomiting. Patients included in VALUE were active smokers despite all of them had a severe COPD which suggests a very high degree of dependence. Although the study do not allow to infer the results to the global population of smokers with severe COPD, the outcomes have shown that, at 24 weeks follow up 36.8% of the patients were successful in quitting but from 79 patients enrolled initially only 17.7% quit.
